Targeting the Ccl6/Ccr2 axis may help delay the progression of renal fibrosis post-AKI and provide novel theoretical insights and potential therapeutic targets for mitigating the transition from AKI to CKD and developing anti-fibrotic therapies, pending validation in future functional studies. This evidence concerns the gene CCR2 and chronic kidney disease.